A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationRituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Self-citationWatts, R., Lane, S., Hanslik, T., Hauser, T., Hellmich, B., Koldingsnes, W., Mahr, A., Segelmark, M., Cohen-Tervaert, J. W., & Scott, D. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.054593 · Cited by 1,359
Self-citationModification and validation of the Birmingham Vasculitis Activity Score (version 3)
Mukhtyar, C., Lee, R., Brown, D., Carruthers, D., Dasgupta, B., Dubey, S., Flossmann, O., Hall, C., Hollywood, J., Jayne, D., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101279 · Cited by 1,224
Self-citationEULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
“25 mg/kg per day by 12 weeks) and 93% were in remission by six months (76).”
BackgroundSelf-citationJayne, D. R. W., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C. O. S., Sinico, R. A., Stegeman, C. A., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010090 · Cited by 1,125
Self-citationRituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Genetically Distinct Subsets within ANCA-Associated Vasculitis
Lyons, P. A., Rayner, T. F., Trivedi, S., Holle, J. U., Watts, R. A., Jayne, D. R. W., Baslund, B., Brenchley, P., Bruchfeld, A., Chaudhry, A. N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108735 · Cited by 1,010
Self-citationEULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
“It is common practice to commence prednisolone or prednisone at 1 mg/kg/day as in recent clinical trials.(31) 33 56 The initial high dose should be maintained for”
BackgroundInfluentialSelf-citationKitching, A. R., Anders, H.-J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0204-y · Cited by 928
Self-citationde Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Self-citationGuillevin, L., Pagnoux, C., Seror, R., Mahr, A., Mouthon, L., & Toumelin, P. L. (2011) · Medicine · doi:10.1097/md.0b013e318205a4c6 · Cited by 951
“Ophthalmologic manifestations 32 (9) 13 (6) 19 (8) 97 (31) 161 (15)”
Long-term patient survival in ANCA-associated vasculitis
Flossmann, O., Berden, A., de Groot, K., Hagen, C., Harper, L., Heijl, C., Höglund, P., Jayne, D., Luqmani, R., Mahr, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137778 · Cited by 939
Self-citationHistopathologic Classification of ANCA-Associated Glomerulonephritis
Berden, A. E., Ferrario, F., Hagen, E. C., Jayne, D. R., Jennette, J. C., Joh, K., Neumann, I., Noël, L.-H., Pusey, C. D., Waldherr, R., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050477 · Cited by 917
“Focal 8 (50) 7 ( 44) 0 (0) 1 ( 6) 16 (100) Crescentic 3 ( 6) 29 ( 53) 8 ( 15) 15 ( 27) 55 (100) Mixed 1 ( 6) 7 ( 44) 4 (25) 4 (25) 16 (100) Sclerotic 0 (0) 4 (31) 4 (31) 5 (39) 13 (100) SPECIAL ARTICLE www.”
Self-citationPlasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Walsh, M., Merkel, P. A., Peh, C.-A., Szpirt, W. M., Puéchal, X., Fujimoto, S., Hawley, C. M., Khalidi, N., Floßmann, O., Wald, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1803537 · Cited by 893
Self-citationKDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 893
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
De Groot, K., Rasmussen, N., Bacon, P. A., Tervaert, J. W. C., Feighery, C., Gregorini, G., Gross, W. L., Luqmani, R., & Jayne, D. R. W. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21142 · Cited by 801
“Recently, a higher relapse rate in WG compared with MPA in PR3 cANCA–positive disease compared with MPO pANCA–positive disease has been reported by several groups (16,29,30).”
BackgroundMethodResultSelf-citationEULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223764 · Cited by 768
Self-citationEfficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
Sinico, R. A., Di Toma, L., Maggiore, U., Bottero, P., Radice, A., Tosoni, C., Grasselli, C., Pavone, L., Gregorini, G., Monti, S., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21250 · Cited by 691
Self-citationAzathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis
Dhawan, R. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79350-2 · Cited by 674
Hellmich, B., Flossmann, O., Gross, W. L., Bacon, P., Willem Cohen-Tervaert, J., Guillevin, L., Jayne, D., Mahr, A., Merkel, P. A., Raspe, H., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062711 · Cited by 633
Self-citationHiemstra, T. F., Walsh, M., Mahr, A., Savage, C. O., de Groot, K., Harper, L., Hauser, T., Neumann, I., Tesar, V., Wissing, K.-M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1658 · Cited by 596
Self-citationInternational Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Lara, A. R., & Schwarz, M. I. (2010) · Chest · doi:10.1378/chest.08-2084 · Cited by 530
The antineutrophil cytoplasmic antibody–associated vasculitides
Seo, P., & Stone, J. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.030 · Cited by 496
“, 3 to 6 months), followed by longer periods of treatment with either azathioprine (64) or methotrexate (65) to maintain disease remission.”
BackgroundHogan, S. L., Falk, R. J., Chin, H., Cai, J., Jennette, C. E., Jennette, J. C., & Nachman, P. H. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-9-200511010-00005 · Cited by 479
“Kidney-limited, n (%) 89 (25) 28 (37) 54 (21) 11 (10) 35 (29) 8 (29)”
Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476
“Since the CYCAZAREM trial (which did not include EGPA patients) demonstrated that azathioprine (2 mg/kg/day) was as effective as cyclophosphamide for preventing relapses, cyclophosphamide is now used to induce vasculitis remission but not for longer-term remission maintenance [56].”
BackgroundSelf-citationMurayama, K. M. (2007) · Cited by 477
Keogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20718 · Cited by 450
Little, M. A., Nightingale, P., Verburgh, C. A., Hauser, T., De Groot, K., Savage, C., Jayne, D., & Harper, L. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.109389 · Cited by 440
“Other (%) 4 (7) 3 (9) 0 (0) 1 (7) 0 (0)”
Self-citationMukhtyar, C., Flossmann, O., Hellmich, B., Bacon, P., Cid, M., Cohen-Tervaert, J. W., Gross, W. L., Guillevin, L., Jayne, D., Mahr, A., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071936 · Cited by 419
“The latter was directly compared to the relapse rate in WG (18% at 18 months), demonstrating that WG has a higher rate of relapse than MPA (level of evidence = 2B.(14)”
BackgroundResultInfluentialSelf-citationSmith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22046 · Cited by 400
Self-citationRituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
“To this day, the combination of glucocorticoids and cyclophosphamide remains the standard therapy for patients with severe WG or MPA (2, 3).”
BackgroundSuppiah, R., Robson, J. C., Grayson, P. C., Ponte, C., Craven, A., Khalid, S., Judge, A., Hutchings, A., Merkel, P. A., Luqmani, R. A., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221796 · Cited by 364
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
Lapraik, C., Watts, R., Bacon, P., Carruthers, D., Chakravarty, K., D’Cruz, D., Guillevin, L., Harper, L., Jayne, D., Luqmani, R., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem146a · Cited by 369
“TABLE 4. Oral prednisolone regimen [ 24 , 26] (B)”
BackgroundMethodInfluentialSelf-citationTakayasu arteritis—advances in diagnosis and management
Mason, J. C. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.82 · Cited by 367
Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis
Walsh, M., Flossmann, O., Berden, A., Westman, K., Höglund, P., Stegeman, C., Jayne, D., & European Vasculitis Study Group (2012) · Arthritis & Rheumatism · doi:10.1002/art.33361 · Cited by 363
Self-citationANCA Glomerulonephritis and Vasculitis
Jennette, J. C., & Nachman, P. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02500317 · Cited by 360
Booth, A., Harper, L., Hammad, T., Bacon, P., Griffith, M., Levy, J., Savage, C., Pusey, C., & Jayne, D. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000114554.67106.28 · Cited by 359
“The introduction of steroids and cyclophosphamide results in disease remission in 80% of patients by 3 mo and in 95% by 6 mo (15).”
BackgroundMethodInfluentialSelf-citationClinical features and outcome of patients with both ANCA and anti-GBM antibodies
Levy, J. B., Hammad, T., Coulthart, A., Dougan, T., & Pusey, C. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00917.x · Cited by 357
“This is in marked contrast to patients with pure ANCA-related disease (without anti-GBM antibodies), in whom 75% of those presenting dialysis-dependent will recover renal function with appropriate immunosuppression [15], but similar to the outcome in pure anti-GBM disease in which renal recovery is rare from severe re…”
ResultSelf-citationAntineutrophil cytoplasmic antibodies
Bosch, X., Guilabert, A., & Font, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69114-9 · Cited by 354
Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report
Klion, A. D., Bochner, B. S., Gleich, G. J., Nutman, T. B., Rothenberg, M. E., Simon, H.-U., Wechsler, M. E., Weller, P. F., & the Hypereosinophilic Syndromes Working Group (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.042 · Cited by 342
“Because cyclophosphamide is associated with an increased susceptibility to infection, the development of cytopenias, malignancy, and hemorrhagic cystitis, other cytotoxic agents (eg, azathioprine) with a more favorable side-effect profile should be considered for maintenance therapy.(37)”
BackgroundCohen, P., Pagnoux, C., Mahr, A., Arène, J., Mouthon, L., Le Guern, V., André, M., Gayraud, M., Jayne, D., Blöckmans, D., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22679 · Cited by 322
Self-citationMohammad, A. J., Jacobsson, L. T. H., Westman, K. W. A., Sturfelt, G., & Segelmark, M. (2009) · Rheumatology · doi:10.1093/rheumatology/kep304 · Cited by 304
Self-citationANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients
Cornec, D., Gall, E. C.-L., Fervenza, F. C., & Specks, U. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.123 · Cited by 294
Robson, J., Doll, H., Suppiah, R., Flossmann, O., Harper, L., Höglund, P., Jayne, D., Mahr, A., Westman, K., & Luqmani, R. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203927 · Cited by 291
Self-citationCartin‐Ceba, R., Golbin, J. M., Keogh, K. A., Peikert, T., Sánchez‐Menéndez, M., Ytterberg, S. R., Fervenza, F. C., & Specks, U. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34584 · Cited by 291
Jones, R. B., Furuta, S., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206404 · Cited by 277
Self-citationLittle, M. A., Smyth, C. L., Yadav, R., Ambrose, L., Cook, H. T., Nourshargh, S., & Pusey, C. D. (2005) · Blood · doi:10.1182/blood-2005-03-0921 · Cited by 276
Self-citationHolle, J. U., Gross, W. L., Latza, U., Nölle, B., Ambrosch, P., Heller, M., Fertmann, R., & Reinhold‐Keller, E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.27763 · Cited by 270
Self-citationTreatment strategies for autoimmune encephalitis
Shin, Y.-W., Lee, S.-T., Park, K.-I., Jung, K.-H., Jung, K.-Y., Lee, S. K., & Chu, K. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 266
Unizony, S., Villarreal, M., Miloslavsky, E. M., Lu, N., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208073 · Cited by 267
Finkielman, J. D., Merkel, P. A., Schroeder, D., Hoffman, G. S., Spiera, R., St. Clair, E. W., Davis, J. C., McCune, W. J., Lears, A. K., Ytterberg, S. R., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00005 · Cited by 265
“In addition, the number of patients who were positive for ANCA against myeloperoxidase was too small for meaningful longitudinal analysis (5, 28, 29).”
BackgroundSmith, R. M., Jones, R. B., Guerry, M., Laurino, S., Catapano, F., Chaudhry, A., Smith, K. G. C., & Jayne, D. R. W. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34583 · Cited by 250
Self-citationDiagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis)
Lutalo, P. M. K., & D'Cruz, D. P. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.028 · Cited by 246
Central Nervous System Involvement in Wegener Granulomatosis
Seror, R., Mahr, A., Ramanoelina, J., Pagnoux, C., Cohen, P., & Guillevin, L. (2006) · Medicine · doi:10.1097/01.md.0000200166.90373.41 · Cited by 248
Collard, H. R., & Schwarz, M. I. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.04.007 · Cited by 239
Walsh, M., Merkel, P. A., Mahr, A., & Jayne, D. (2010) · Arthritis Care & Research · doi:10.1002/acr.20176 · Cited by 241
“Sneller et al, 1995 (25) 42 30 35 52 100 0 52 46 De Groot et al, 1996 (26) 22/11 22/11 45 39 100 0 NR 100 Guillevin et al, 1997 (23) 50 42 54 40 100 0 74 100 Reinhold-Keller et al, 2002 (27) 71 71 49 42 100 0 NR 75 Guillevin et al, 2003 (24) 47 56 55 47 0 100 83 100 Jayne et al, 2003 (15) 155 145 58 53 61 39 94 100 La…”
BackgroundInfluentialSelf-citationINDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
Baru, P. C. R. (2014) · ADVANCED SCIENCES INDEX · Cited by 236
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
Broen, J. C. A., & van Laar, J. M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0374-8 · Cited by 235
Bourgarit, A., Toumelin, P. L., Pagnoux, C., Cohen, P., Mahr, A., Guern, V. L., Mouthon, L., & Guillevin, L. (2005) · Medicine · doi:10.1097/01.md.0000180793.80212.17 · Cited by 238
“Renal involvement 10/18 (56)y 43/176 (24) 7/20 (35) 32/89 (36) 13/13 (100)y 80/135 (59) 2/9 (22) 21/123 (17) Severe GI involvement 7/18 (39)y 48/176 (27) 13/20 (65)z 42/89 (47) 4/13 (30)z 25/135 (19) 6/9 (67)y 26/123 (21)”
Pagnoux, C., Guilpain, P., & Guillevin, L. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3280119854 · Cited by 236
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
Beck, L., Bomback, A. S., Choi, M. J., Holzman, L. B., Langford, C., Mariani, L. H., Somers, M. J., Trachtman, H., & Waldman, M. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.002 · Cited by 234
“Azathioprine is as effective as prolonged use of cyclophosphamide in maintaining remission.(177) Testing for thiopurine S-methyltransferase, an enzyme responsible for the metabolism of azathioprine, is a widely available in the United States and should be performed when possible as low or absent levels of this enzyme…”
BackgroundYates, M., & Watts, R. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-1-60 · Cited by 231
“Cyclophosphamide The CYCAZAREM trial showed that oral daily cyclophosphamide (2mg/kg/day) for 3-6 months with glucocorticoids achieved remission in more than 90% of patients (8).”
BackgroundERIKSSON, P. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01494.x · Cited by 232
Mahr, A., Katsahian, S., Varet, H., Guillevin, L., Hagen, E. C., Höglund, P., Merkel, P. A., Pagnoux, C., Rasmussen, N., Westman, K., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201750 · Cited by 232
Self-citationJones, R. B., Hiemstra, T. F., Ballarin, J., Blockmans, D. E., Brogan, P., Bruchfeld, A., Cid, M. C., Dahlsveen, K., de Zoysa, J., Espigol-Frigolé, G., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214245 · Cited by 228
“6 25 Our results demonstrate that MMF represents an alternative to CYC for remission induction in AAV.”
Self-citationFloege, J., Jayne, D. R. W., Sanders, J.-S. F., Tesar, V., & Rovin, B. H. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.008 · Cited by 218
“…azathioprine as maintenance therapy was moderate for relapse, in RCTs that compared azathioprine with cyclophosphamide (Supplementary Table S14 22,57 ), methotrexate (Supplementary Table S16 22,59 ), and MMF (Supplementary Table S15 22,58 ), and RCTs that compared extended with standard…”
BackgroundSelf-citationSuppiah, R., Robson, J. C., Grayson, P. C., Ponte, C., Craven, A., Khalid, S., Judge, A., Hutchings, A., Merkel, P. A., Luqmani, R. A., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.41983 · Cited by 218
Anti-glomerular basement membrane disease
Pusey, C. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00241.x · Cited by 224
Self-citationMetzler, C., Miehle, N., Manger, K., Iking-Konert, C., de Groot, K., Hellmich, B., Gross, W. L., Reinhold-Keller, E., & for the German Network of Rheumatic Diseases (2007) · Rheumatology · doi:10.1093/rheumatology/kem029 · Cited by 220
Self-citationStasi, R., Stipa, E., Del Poeta, G., Amadori, S., Newland, A. C., & Provan, D. (2006) · Rheumatology · doi:10.1093/rheumatology/kel098 · Cited by 219
“Conversely, immunosuppressive therapy bears potential complications such as neutropaenic fever, herpes zoster, myelodysplasia and cataracts; deaths as a result of sepsis have also been described [1, 20, 21].”
BackgroundKarras, A., Pagnoux, C., Haubitz, M., Groot, K. D., Puechal, X., Tervaert, J. W. C., Segelmark, M., Guillevin, L., & Jayne, D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211123 · Cited by 211
Self-citationMonach, P. A., Arnold, L. M., & Merkel, P. A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25061 · Cited by 211
Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides
Kallenberg, C. G., Heeringa, P., & Stegeman, C. A. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0355 · Cited by 208
Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis
Hilhorst, M., van Paassen, P., & Tervaert, J. W. C. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090903 · Cited by 206
Self-citationUrinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide
Knight, A., Askling, J., Granath, F., Sparen, P., & Ekbom, A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019125 · Cited by 204
Park, M. S. (2013) · Tuberculosis and Respiratory Diseases · doi:10.4046/trd.2013.74.4.151 · Cited by 199
Seo, P., Min, Y., Holbrook, J. T., Hoffman, G. S., Merkel, P. A., Spiera, R., Davis, J. C., Ytterberg, S. R., St. Clair, E. W., McCune, W. J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21117 · Cited by 202
Tarabishy, A. B., Schulte, M., Papaliodis, G. N., & Hoffman, G. S. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.12.003 · Cited by 197
“Relapse rates were w15% at 18 months in both groups, demonstrating that after a brief period of treatment with cyclophosphamide, alternative therapy with a less risky agent did not sacrificing efficacy.(33) Methotrexate and azathioprine have recently been shown to be equally effective in maintenance of remission.”
BackgroundWalsh, M., Catapano, F., Szpirt, W., Thorlund, K., Bruchfeld, A., Guillevin, L., Haubitz, M., Merkel, P. A., Peh, C. A., Pusey, C., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.10.049 · Cited by 196
Self-citationPagnoux, C., Quéméneur, T., Ninet, J., Diot, E., Kyndt, X., de Wazières, B., Reny, J., Puéchal, X., le Berruyer, P., Lidove, O., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39011 · Cited by 196
“The corticosteroid regimen in most European trials on ANCAassociated vasculitis exceeded 12 months (8,16,32), as in our trial, as opposed to only 6 months in several US trials (33,34).”
BackgroundResultInfluentialTreatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Systematic Review
Bosch, X., Guilabert, A., Espinosa, G., & Mirapeix, E. (2007) · JAMA · doi:10.1001/jama.298.6.655 · Cited by 196
“Systemic Vasculitis) study by Jayne et al.(9) Seventy-three patients were randomly assigned to continue cyclo-”
BackgroundMethodInfluentialSelf-citationANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients
Harper, L., & Savage, C. O. (2005) · Rheumatology · doi:10.1093/rheumatology/keh522 · Cited by 194
“As in other studies relapse was more common in patients with Wegener’s granulomatosis (OR 2.1, CI 1.58–2.9; P ¼ 0.0001) [4, 12 ].”
ResultInfluentialSystemic Rheumatoid Vasculitis: A Review
Genta, M. S., Genta, R. M., & Gabay, C. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.04.006 · Cited by 194
Wegener’s Granulomatosis: Ophthalmic Manifestations and Management
Pakrou, N., Selva, D., & Leibovitch, I. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.12.003 · Cited by 190
Azathioprine in dermatology: The past, the present, and the future
Patel, A. A., Swerlick, R. A., & McCall, C. O. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.07.059 · Cited by 188
Renal Involvement in Churg-Strauss Syndrome
Sinico, R. A., Toma, L. D., Maggiore, U., Tosoni, C., Bottero, P., Sabadini, E., Giammarresi, G., Tumiati, B., Gregorini, G., Pesci, A., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.01.026 · Cited by 185
Self-citationEosinophils in vasculitis: characteristics and roles in pathogenesis
Khoury, P., Grayson, P. C., & Klion, A. D. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.98 · Cited by 182
ANCA-Associated Vasculitis: An Update
Almaani, S., Fussner, L. A., Brodsky, S., Meara, A. S., & Jayne, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071446 · Cited by 181
Self-citationMortality in systemic vasculitis: a systematic review.
Phillip, R., & Luqmani, R. A. (2008) · PubMed · Cited by 179
Suppiah, R., Judge, A., Batra, R., Flossmann, O., Harper, L., Höglund, P., Javaid, M. K., Jayne, D., Mukhtyar, C., Westman, K., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20433 · Cited by 175
“generalized life-threatening disease (4), 3) CYCLOPS: in-”
Self-citationRituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Smith, R. M., Jones, R. B., Specks, U., Bond, S., Nodale, M., Aljayyousi, R., Andrews, J., Bruchfeld, A., Camilleri, B., Carette, S., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216863 · Cited by 174
“5 (5-13) for patients treated with rituximab), makes direct comparison between RITAZAREM and RAVE difficult.”
BackgroundSelf-citationMycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
Langford, C. A., Talar‐Williams, C., & Sneller, M. C. (2004) · Arthritis Care & Research · doi:10.1002/art.20240 · Cited by 174
ANCA-associated vasculitis with renal involvement: an outcome analysis
Weidner, S., Geuss, S., Hafezi-Rachti, S., Wonka, A., & Rupprecht, H. D. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh161 · Cited by 173
Martinez, V., Cohen, P., Pagnoux, C., Vinzio, S., Mahr, A., Mouthon, L., Sailler, L., Delaunay, C., Sadoun, A., Guillevin, L., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23147 · Cited by 175
Sinico, R. A., & Bottero, P. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.02.004 · Cited by 171
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.